InnaMed

Using at-home blood testing technology to enable personalized medicine
Philadelphia, 
PA
Investment type:
Equity
(SAFE)
Target raise:
$100,000
 - $1,070,000
Minimum investment:​
$100
End date:
May 01, 2021
Share
Share on facebook
Share on twitter
Share on linkedin
Share on email
Highlights

  • Raised $2M+, backed by Y Combinator and leading Silicon Valley investors
  • $1.4M+ in revenue in 2020 (6x YoY) from ongoing, multi-year pharmaceutical R&D collaborations
  • Received grants from NASA and US Dept. of Health & Human Services for innovative HomeLab® technology
  • 9 patent applications and 5 peer-reviewed publications on technology
Our Story

InnaMed makes monitoring and analyzing blood test data fast and seamless. Blood monitoring is a key component of getting the right patients on the right therapies at the right doses, but it's far too tedious today. InnaMed’s patented, flagship product, the HomeLab® system, enables push button blood testing in the home.
Our Ambition

InnaMed aims to become a leading telemedicine infrastructure company. We envision HomeLab hardware and software playing a critical role in pharmaceutical clinical trials across the globe. We also aim to have several FDA-cleared products on the market for use across a variety of clinical indications to make achieving optimal treatment of any given patient easier.